{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-011083","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2025-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.347480+00:00","generated_at":"2026-05-24T09:10:44.761882+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biofrontera reports record FY 2024 revenue $37.3M, up 9.5% YoY; Q4 net loss $1.4M","bullets":["Record total revenues $37.3M for 2024, +9.5% from $34.1M in 2023; Q4 revenues $12.6M, +18.5% YoY.","Q4 2024 net loss $1.4M ($0.19/share) vs net income $3.5M ($1.65/share) in Q4 2023 due to prior-year legal settlement gain.","Cash and equivalents $5.9M at Dec 31, 2024 vs $1.3M at Dec 31, 2023; Ameluz transfer price reduced from 50% to 25% through 2025.","Placed 100 RhodoLED XL lamps since June 2024 launch; FDA approved up to 3 tubes of Ameluz per treatment.","Phase 3 Study for Ameluz-PDT in superficial BCC achieved statistically significant results; initiated Phase 1 PK study for AK."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-011083","json":"https://secwatch.observer/filing/0001493152-25-011083.json","markdown":"https://secwatch.observer/filing/0001493152-25-011083.md","text":"https://secwatch.observer/filing/0001493152-25-011083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315225011083/0001493152-25-011083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315225011083/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T09:10:44.761882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}